4QXX

Structure of the amyloid forming peptide GNLVS (residues 26-30) from the eosinophil major basic protein (EMBP)


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.45 Å
  • R-Value Free: 0.192 
  • R-Value Work: 0.164 
  • R-Value Observed: 0.167 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Toxicity of Eosinophil MBP Is Repressed by Intracellular Crystallization and Promoted by Extracellular Aggregation.

Soragni, A.Yousefi, S.Stoeckle, C.Soriaga, A.B.Sawaya, M.R.Kozlowski, E.Schmid, I.Radonjic-Hoesli, S.Boutet, S.Williams, G.J.Messerschmidt, M.Seibert, M.M.Cascio, D.Zatsepin, N.A.Burghammer, M.Riekel, C.Colletier, J.P.Riek, R.Eisenberg, D.S.Simon, H.U.

(2015) Mol Cell 57: 1011-1021

  • DOI: https://doi.org/10.1016/j.molcel.2015.01.026
  • Primary Citation of Related Structures:  
    4QXX

  • PubMed Abstract: 

    Eosinophils are white blood cells that function in innate immunity and participate in the pathogenesis of various inflammatory and neoplastic disorders. Their secretory granules contain four cytotoxic proteins, including the eosinophil major basic protein (MBP-1). How MBP-1 toxicity is controlled within the eosinophil itself and activated upon extracellular release is unknown. Here we show how intragranular MBP-1 nanocrystals restrain toxicity, enabling its safe storage, and characterize them with an X-ray-free electron laser. Following eosinophil activation, MBP-1 toxicity is triggered by granule acidification, followed by extracellular aggregation, which mediates the damage to pathogens and host cells. Larger non-toxic amyloid plaques are also present in tissues of eosinophilic patients in a feedback mechanism that likely limits tissue damage under pathological conditions of MBP-1 oversecretion. Our results suggest that MBP-1 aggregation is important for innate immunity and immunopathology mediated by eosinophils and clarify how its polymorphic self-association pathways regulate toxicity intra- and extracellularly.


  • Organizational Affiliation

    UCLA-DOE Institute, HHMI, and Departments of Biological Chemistry and Chemistry and Biochemistry, 611 Charles E. Young Drive, University of California, Los Angeles, Los Angeles, CA 90095-1570, USA; Institute of Pharmacology, University of Bern, Friedbuehlstrasse 49, 3010 Bern, Switzerland; Department of Physical Chemistry, ETH Zurich, Wolfgang-Pauli-Strasse 10, 8093 Zurich, Switzerland.


Macromolecules

Find similar proteins by:  Sequence   |   3D Structure  

Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Bone marrow proteoglycanA [auth Z]5Homo sapiensMutation(s): 0 
UniProt & NIH Common Fund Data Resources
Find proteins for P13727 (Homo sapiens)
Explore P13727 
Go to UniProtKB:  P13727
PHAROS:  P13727
GTEx:  ENSG00000186652 
Entity Groups  
UniProt GroupP13727
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.45 Å
  • R-Value Free: 0.192 
  • R-Value Work: 0.164 
  • R-Value Observed: 0.167 
  • Space Group: P 2 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 4.755α = 90
b = 16.816β = 90
c = 35.759γ = 90
Software Package:
Software NamePurpose
ADSCdata collection
PHASERphasing
PHENIXrefinement
DENZOdata reduction
SCALEPACKdata scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2015-03-18
    Type: Initial release
  • Version 1.1: 2015-04-08
    Changes: Database references
  • Version 1.2: 2024-02-28
    Changes: Data collection, Database references